Top

Published in:

Open Access 01-12-2020 | Editorial

The clinical and the laboratory autoimmunologist: Where do we stand?

Authors: Renato Tozzoli, Nicola Bizzaro

Published in: Autoimmunity Highlights | Issue 1/2020

Excerpt

As highlighted in many medical reports from industrialized countries, autoimmune diseases (AIDs) are increasing in number (almost 100 distinct AIDs have been classified to date) and in epidemiology (5–10% of individuals worldwide are affected by an AID) [1, 2]. In the United States, AIDs are collectively estimated to affect from 5 to 8% of the population or 15 to 20 million individuals [3] and are cumulatively the third cause of illness and mortality in humans [2, 4]. Consequently, many efforts are produced by health systems for prevention, early diagnosis and treatment of autoimmune diseases. …

Hoyter SM, Cook MC. Uptated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11:754–65.

Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.PubMed

Roberts MH, Erdei E. Comparative United States autoimmune diseases rates for 2010–2016 by sex, geographic region, and race. Autoimmun Rev. 2020;19:102423.PubMed

Thomas SL, Griffiths C, Smeeth L, Rooney C, Hall AJ. Burden of mortality associated with autoimmune diseases among females in the United Kingdom. Am J Public Health. 2010;100:2279–87.PubMedPubMedCentral

Shoenfeld Y, Selmi C, Zimlichman F, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time of autoimmunity. J Autoimmun. 2008;31:325–30.PubMed

Shoenfeld Y. The autoimmunologist: a profession being created. Harefuah. 2009;148:796–7.

Selmi C, Gershwin ME. The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias. Clin Rev Allerg Immunol. 2012;43:207–10.

Watad A, Bragazzi NL, Adawi M, Amital H, Kivity S, Mahroum N, et al. Is autoimmunology a discipline of its own? A big data-based bibliometric and scientometric analyses. Autoimmunity. 2017;50:269–74.PubMed

Rose NR. Prediction and prevention of autoimmune disease in the 21^st century: a review and preview. Am J Epidemiol. 2016;183:403–6.PubMed

10.

Tozzoli R, D’Aurizio F, Villalta D, Bizzaro N. Automation, consolidation, and integration in autoimmune diagnostics. Auto Immun Highlights. 2015;6:1–6.PubMedPubMedCentral

11.

Barabas AZ, Cole CD, Graeff RM, Lafreniere R, Weir DM. The role of autoimmunologists in investigating and treating autoimmune disorders. Autoimmun Rev. 2011;10:166–70.PubMed

12.

Tozzoli R, Bizzaro N. The clinical autoimmunologist and the laboratory autoimmunologist: the two sides of the coin. Autoimmun Rev. 2012;11:766–70.PubMed

13.

Vasconcelos C. Do we need autoimmune disease units in hospitals? Ann N Y Acad Sci. 2009;1173:4–9.PubMed

14.

Damoiseaux J, Olschowka N, Shoenfeld Y. EASI—European Autoimmunity Standardisation Initiative: facing the challenges of diagnostics in autoimmunity. Clin Chem Lab Med. 2018;56:1620–3.PubMed

15.

Damoiseaux J. The perspective on standardisation and harmonisation: the viewpoint of the EASI president. Auto Immun Highlights. 2020;11:4.PubMedPubMedCentral

16.

Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77:175–87.PubMed

17.

De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195:74–85.PubMed

18.

Barnas JL, Looney RJ, Anolik JH. B cell targeted therapies in autoimmune disease. Curr Opin Immunol. 2019;61:92–9.PubMedPubMedCentral

19.

Tozzoli R, Sorrentino MC, Bizzaro N. Detecting multiple autoantibodies to diagnose autoimmune comorbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist. Immunol Res. 2013;56:425–31.PubMed

20.

Scott MG, Rifai N, Smith B, Oellerich M, Panteghini M, Apple F, et al. The changing face of laboratory medicine: a more service and less academically oriented profession? Clin Chem. 2015;6:322–9.

21.

Bizzaro N, Tozzoli R, Villalta D. Autoimmune diagnostics: the technology, the strategy and the clinical governance. Immunol Res. 2015;61:126–34.PubMed

22.

Boursier G, Vukasovic I, Brguljan PM, Lohmander M, Ghita I, Bernabeu Andreu FA, et al. Accreditation process in European countries—an EFLM survey. Clin Chem Lab Med. 2016;54:545–51.PubMed

23.

Bizzaro N, Bossuyt X, Haapala A-M, Shoenfeld Y, Sack U. Accreditation in autoimmune diagnostic laboratories. A position paper of the European Autoimmunity Standardisation Initiative (EASI). Autoimmun Rev. 2017;16:81–6.PubMed

24.

Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, et al. Quality and best practice in medical laboratories—specific requests for autoimmunity testing. Auto Immun Highlights 2020.

25.

Bizzaro N, Morozzi G. A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases. Rheumatol Int. 2009;29:849–51.PubMed

26.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400–12.PubMedPubMedCentral

27.

Bizzaro N, Brusca I, Previtali G, Alessio MG, Daves M, Platzgummer S, et al. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoimmun Rev. 2018;17:541–7.PubMed

28.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018;75:1528–37.PubMedPubMedCentral

29.

Bidoli E, Villalta D. Epidemiological and ethical aspects of multiplex autoantibody testing. Autoimmun Rev. 2007;6:354–8.PubMed

30.

Bizzaro N. Autoantibody profiles in autoimmune rheumatic diseases. Mediterr J Rheumatol. 2019;30:86–9.PubMedPubMedCentral

31.

Chan EL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412.PubMedPubMedCentral

32.

Damoiseaux J, von Mühlen CA, De La Garcia Torre I, Carballo OG, de Melo Cruvinel W, Francescantonio PL, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016;7:1.PubMedPubMedCentral

33.

Damoiseaux J, Andrade JEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78:879–89.PubMed

34.

Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev. 2009;8:5438.

35.

Bossuyt X, Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K, et al. Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmun Rev. 2019;18:102386.PubMed

36.

Tozzoli R, Villalta D, Bizzaro N. Challenges in the standardization of autoantibody testing: a comprehensive review. Clin Rev Allergy Immunol. 2017;53:68–77.PubMed

37.

Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? Arthr Res Ther. 2009;11:252.

38.

Ørstavik KH. Why are autoimmune diseases more prevalent in women? Tidsskr Nor Laegeforen. 2017;137:866–8.PubMed

39.

Tozzoli R, Giavarina D, Villalta D, Soffiati G, Bizzaro N. Definition of reference limits for autoantibodies to thyroid peroxidase and thyroglobulin in a large population of outpatients using an indirect method based on current data. Arch Pathol Lab Med. 2008;132:1924–8.PubMed

40.

Bizzaro N, Wiik A. Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol. 2004;22:349–55.PubMed

41.

Sinclair D, Duncan H. What happens to patients with positive tissue transglutaminase and endomysium antibody results in general practice? J Clin Pathol. 2004;57:943–5.PubMedPubMedCentral

42.

Hickner J, Thompson PJ, Wilkinson T, Epner P, Sheehan M, Pollock AM, et al. Primary care physicians’ challenges in ordering clinical laboratory tests and interpreting results. J Am Board Fam Med. 2014;27:268–74.PubMed

43.

Betterle C, Presotto E. Update on autoimmune polyglandular syndromes (APS). Acta Bio Med. 2003;74:9–33.

44.

Bagnasco M, Grassia L, Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev. 2007;6:347–53.PubMed

45.

Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24–32.PubMed

46.

Tozzoli R, Kodermaz G, Perosa AR, Tampoia M, Zucano A, Antico A, et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;10:80–3.PubMed

47.

Zaninotto M, Plebani M. Understanding and managing interferences in clinical laboratory assays: the role of laboratory professionals. Clin Chem Lab Med. 2020;58:350–6.PubMed

48.

Censi S, Cavedon E, Fernando SW, Barollo S, Bertazza L, Zambonin L, et al. Calcitonin measurement and immunoassay interference: a case report and literature review. Clin Chem Lab Med. 2016;54:1861–70.PubMed

49.

Warda G, Simpson A, Boscatoc L, Hickman PE. The investigation of interferences in immunoassay. Clin Biochem. 2017;50:1306–11.

50.

Luong JH, Male KB, Glennon JD. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: an emerging threat. Biotechnol Adv. 2019;37:634–41.PubMed

51.

Sciacovelli L, Aita A, Padoan A, Pelloso M, Antonelli G, Piva E, et al. Performance criteria and quality indicators for the post-analytical phase. Clin Chem Lab Med. 2016;54:1169–76.PubMed

Title: The clinical and the laboratory autoimmunologist: Where do we stand?
Authors: Renato Tozzoli
Nicola Bizzaro
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Autoimmunity Highlights / Issue 1/2020
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI: https://doi.org/10.1186/s13317-020-00133-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The clinical and the laboratory autoimmunologist: Where do we stand?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Associations between HLA and autoimmune neurological diseases with autoantibodies

Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey

Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro

Quality and best practice in medical laboratories: specific requests for autoimmunity testing

Receptor autoimmunity: diagnostic and therapeutic implications

Castleman disease and SLE in a G6PD-deficient Marfan patient: a case report and literature review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page